Literature DB >> 30419097

Vaccines as an Integral Component of Cancer Immunotherapy.

Jeffrey Schlom1, James L Gulley2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30419097      PMCID： PMC6538063          DOI： 10.1001/jama.2018.9511

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  10 in total

Review 1.  Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.

Authors:  Colby S Shemesh; Joy C Hsu; Iraj Hosseini; Ben-Quan Shen; Anand Rotte; Patrick Twomey; Sandhya Girish; Benjamin Wu
Journal:  Mol Ther       Date:  2020-09-30       Impact factor: 11.454

2.  Design for immuno-oncology clinical trials enrolling both responders and nonresponders.

Authors:  Zhenzhen Xu; Bin Zhu; Yongsoek Park
Journal:  Stat Med       Date:  2020-09-17       Impact factor: 2.497

Review 3.  Radiotherapy for Melanoma: More than DNA Damage.

Authors:  Susanne J Rogers; Emsad Puric; Brigitte Eberle; Niloy R Datta; Stephan B Bodis
Journal:  Dermatol Res Pract       Date:  2019-04-03

4.  A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.

Authors:  Margaret E Gatti-Mays; Jason M Redman; Jeffrey Schlom; James L Gulley; Renee N Donahue; Claudia Palena; Ravi A Madan; Fatima Karzai; Marijo Bilusic; Houssein Abdul Sater; Jennifer L Marté; Lisa M Cordes; Sheri McMahon; Seth M Steinberg; Alanvin Orpia; Andrea Burmeister; Julius Strauss
Journal:  Oncologist       Date:  2019-10-08

5.  Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment.

Authors:  Robert Owen Dillman; Candace Hsieh
Journal:  Biomedicines       Date:  2019-10-11

6.  Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology.

Authors:  Keman Cheng; Ruifang Zhao; Yao Li; Yingqiu Qi; Yazhou Wang; Yinlong Zhang; Hao Qin; Yuting Qin; Long Chen; Chen Li; Jie Liang; Yujing Li; Jiaqi Xu; Xuexiang Han; Gregory J Anderson; Jian Shi; Lei Ren; Xiao Zhao; Guangjun Nie
Journal:  Nat Commun       Date:  2021-04-06       Impact factor: 17.694

7.  A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells.

Authors:  Joshua R Veatch; Naina Singhi; Shivani Srivastava; Julia L Szeto; Brenda Jesernig; Sylvia M Stull; Matthew Fitzgibbon; Megha Sarvothama; Sushma Yechan-Gunja; Scott E James; Stanley R Riddell
Journal:  J Clin Invest       Date:  2021-08-16       Impact factor: 14.808

8.  Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies.

Authors:  Chisato Yokota; Jun Nakata; Koji Takano; Hiroko Nakajima; Hiromu Hayashibara; Hikaru Minagawa; Yasuyoshi Chiba; Ryuichi Hirayama; Noriyuki Kijima; Manabu Kinoshita; Yoshiko Hashii; Akihiro Tsuboi; Yoshihiro Oka; Yusuke Oji; Atsushi Kumanogoh; Haruo Sugiyama; Naoki Kagawa; Haruhiko Kishima
Journal:  Neurooncol Adv       Date:  2021-06-29

Review 9.  Antitumor Peptide-Based Vaccine in the Limelight.

Authors:  Takumi Kumai; Hidekiyo Yamaki; Michihisa Kono; Ryusuke Hayashi; Risa Wakisaka; Hiroki Komatsuda
Journal:  Vaccines (Basel)       Date:  2022-01-03

Review 10.  Immunology of Lynch Syndrome.

Authors:  Danielle M Pastor; Jeffrey Schlom
Journal:  Curr Oncol Rep       Date:  2021-06-14       Impact factor: 5.075
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.